Despite the encouraging results in melanoma, non-small cell lung cancer (NSCLC), kidney and urothelial cancers [16,17], the use of single-agent antibodies inhibiting the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or PD-1 or PD-L1 axis yielded only modest results in EOC with median response rates of 10–15%, and a control of disease observed in less than half of the patients [18,19,20,21]. The gene discussed is CTLA4; the disease is melanoma.